Table 2.
Top-cited papers in inflammatory bowel disease (IBD) identified by searching the Web of Science, summarised by category and topic
| Topics on IBD | Category: no. of articles (references) | ||||
| Article | Review/meta-analysis | Report | Research | Total (%) | |
| Epidemiology, prevalence | 235 38 | 2 (4%) | |||
| CD genetic susceptibility and NOD2 mutation | 234 45 | 420 21 51 54 | 6 (12%) | ||
| Animal models for IBD | 160 | 422 40 44 48 | 5 (10%) | ||
| Pathogenesis of IBD | 725 27 33 36 55 57 63 | 829 32 42 62 64–66 68 | 15 (30%) | ||
| Classification, index of disease activity | 139 | 243 59 | 223 37 | 5 (10%) | |
| Risk of developing colorectal cancer | 141 | 149 | 2 (4%) | ||
| Extraintestinal complications | 161 | 1 (2%) | |||
| Infliximab in CD | 624 30 31 46 47 52 | 6 (12%) | |||
| Corticosteroids in UC | 128 | 1 (2%) | |||
| Drug treatment and ciclosporin in UC | 256 58 | 2 (4%) | |||
| Adalimumab in CD | 153 | 1 (2%) | |||
| 5-Aminosalicylic acid in UC | 150 | 1 (2%) | |||
| 6-Mercaptopurine in CD | 167 | 1 (2%) | |||
| Monoclonal antibodies, antitumour necrosis factor in CD | 226 69 | 2 (4%) | |||
| Total (%) | 1 (2%) | 14 (28%) | 2 (4%) | 33 (66%) | 50 (100%) |
CD, Crohn’s disease; UC, ulcerative colitis.